174 related articles for article (PubMed ID: 21062408)
1. TSLC1 tumour-suppressor gene expression in canine mast cell tumours.
Taylor F; Murphy S; Hoather T; Dobson J; Scase T
Vet Comp Oncol; 2010 Dec; 8(4):263-72. PubMed ID: 21062408
[TBL] [Abstract][Full Text] [Related]
2. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
3. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
[TBL] [Abstract][Full Text] [Related]
4. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours.
Amorim RL; Pinczowski P; Neto RT; Rahal SC
Vet Comp Oncol; 2010 Mar; 8(1):23-7. PubMed ID: 20230578
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours.
Berlato D; Murphy S; Monti P; Stewart J; Newton JR; Flindall A; Maglennon GA
Vet Comp Oncol; 2015 Jun; 13(2):143-50. PubMed ID: 23489679
[TBL] [Abstract][Full Text] [Related]
7. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung.
Uchino K; Ito A; Wakayama T; Koma Y; Okada T; Ohbayashi C; Iseki S; Kitamura Y; Tsubota N; Okita Y; Okada M
Cancer; 2003 Sep; 98(5):1002-7. PubMed ID: 12942568
[TBL] [Abstract][Full Text] [Related]
8. Ki67/KIT double immunohistochemical staining in cutaneous mast cell tumors from Boxer dogs.
Fonseca-Alves CE; Bento DD; Torres-Neto R; Werner J; Kitchell B; Laufer-Amorim R
Res Vet Sci; 2015 Oct; 102():122-6. PubMed ID: 26412531
[TBL] [Abstract][Full Text] [Related]
9. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
[TBL] [Abstract][Full Text] [Related]
10. Widespread mismatch repair protein expression in canine cutaneous mast cell tumors.
Munday JS; French AF; Gibson IR; Gwynne K
Vet Pathol; 2009 Mar; 46(2):227-32. PubMed ID: 19261633
[TBL] [Abstract][Full Text] [Related]
11. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM
Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
[TBL] [Abstract][Full Text] [Related]
13. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
[TBL] [Abstract][Full Text] [Related]
14. Expression of Fibroblast Activating Protein and Correlation with Histological Grade, Mitotic Index and Ki67 Expression in Canine Mast Cell Tumours.
Giuliano A; Dos Santos Horta R; Constantino-Casas F; Hoather T; Dobson J
J Comp Pathol; 2017 Jan; 156(1):14-20. PubMed ID: 27889201
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment.
Teng SP; Hsu WL; Chiu CY; Wong ML; Chang SC
Vet J; 2012 Aug; 193(2):551-6. PubMed ID: 22398132
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
[TBL] [Abstract][Full Text] [Related]
17. TSLC1 gene silencing in cutaneous melanoma.
You Y; Ma L; You M; Li X; Wang S; Li H; Wu D; Yang H; Li ZY
Melanoma Res; 2010 Jun; 20(3):179-83. PubMed ID: 20375924
[TBL] [Abstract][Full Text] [Related]
18. Identification of two molecular subtypes in canine mast cell tumours through gene expression profiling.
Pulz LH; Barra CN; Alexandre PA; Huete GC; Cadrobbi KG; Nishiya AT; de Freitas SH; Fukumasu H; Strefezzi RF
PLoS One; 2019; 14(6):e0217343. PubMed ID: 31216299
[TBL] [Abstract][Full Text] [Related]
19. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers.
Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F
BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical application of an antibody specific for human CD1a to the diagnosis of canine mast cell tumour.
Yhee JY; Hong SW; Yu CH; Doster AR; Blas-Machado U; Lyoo YS; Sur JH
J Comp Pathol; 2008 Jul; 139(1):40-6. PubMed ID: 18602642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
